Your body is trying to tell you something. Listen to it.
For decades, one in ten women worldwide carried a diagnosis whose very name pointed them toward the wrong understanding of their own bodies. Last month, the medical establishment formally corrected that misdirection, renaming polycystic ovary syndrome — PCOS — as polyendocrine metabolic ovarian syndrome, or PMOS, following a landmark global survey published in The Lancet. The change acknowledges what research has long shown: this is a systemic hormonal and metabolic condition, not merely an ovarian one. In renaming it, medicine is not simply updating a label — it is offering millions of women a more truthful map of their own suffering, and a clearer path toward care.
- For years, a misleading name sent doctors and patients alike chasing the wrong part of the body, leaving the metabolic and hormonal roots of the condition largely unaddressed.
- Women like Ashleigh Martin faced the compounding trauma of sudden weight gain, fertility fears, and a diagnosis that felt like a verdict — all without an accurate framework to understand what was actually happening inside them.
- A global survey of over 14,000 affected women helped drive a formal rename, published in The Lancet, signalling that the medical world can no longer treat this as a niche reproductive footnote.
- The new name — PMOS — opens the door to broader screening for insulin resistance, inflammation, and endocrine dysfunction, pushing care beyond symptom management toward systemic treatment.
- Martin's own recovery through lifestyle intervention, achieved without pharmaceutical shortcuts, now stands as evidence that when women are given the full picture, they can begin to heal it.
At 22, Ashleigh Martin's body began to change in ways she couldn't explain. Her periods grew erratic, and within six months she had gained 35 kilograms. An ultrasound revealed twenty cysts on each ovary, and the radiologist's prognosis was devastating: possible infertility, possible malignancy. The fear that followed was the kind that reshapes a person.
She was far from alone. One in ten women globally share her diagnosis — a condition that, until last month, carried a name doctors now acknowledge was fundamentally misleading. Polycystic ovary syndrome, or PCOS, framed the problem as one of ovarian cysts. But the cysts were rarely the whole story. Beneath them lay insulin resistance, chronic inflammation, and endocrine imbalance that the old name had quietly obscured for decades.
Following a global survey of more than 14,360 women, the condition has been formally renamed polyendocrine metabolic ovarian syndrome — PMOS — in a paper published in The Lancet. The change is being hailed as a watershed for women's health. By naming the systemic nature of the condition, the new terminology aims to end the fragmented care that left countless women waiting years for diagnosis, or receiving one with little guidance on what to do next. The stigma of PCOS — which sounded like reproductive failure, something to be whispered about — ran deep, and doctors often treated only the most visible symptoms rather than the metabolic dysfunction driving them.
Martin, now 34 and based in Singapore, eventually rebuilt her relationship with her body through sustained lifestyle change rather than pharmaceutical intervention. She became a personal trainer. Her journey from terror to agency is precisely the kind of story the rebranding was designed to make more possible — for her, and for every woman whose body begins to rebel before she has the language to understand why.
At 22, Ashleigh Martin's body stopped cooperating. Her periods became unpredictable. Within six months, she had gained 35 kilograms—more than 77 pounds—without understanding why. An ultrasound delivered the shock: twenty cysts clustered on each ovary. The radiologist's words landed harder than the diagnosis itself. She might never have children. The cysts could turn cancerous. Martin, who was working then as a VIP account manager in food and beverage while modeling and hosting events, remembers the terror of that moment with the clarity that only real fear leaves behind.
She was not alone in that fear, though she didn't know it yet. One in ten women globally carry the same diagnosis. For decades, they have carried it under a name that doctors now say was fundamentally misleading: polycystic ovary syndrome, or PCOS. The name suggested the problem was in the ovaries—the cysts themselves. But the cysts were never the whole story, and often not even the main one.
Last month, after a global survey of more than 14,360 women living with the condition, the medical establishment formally renamed it. Polyendocrine metabolic ovarian syndrome—PMOS—is the new term, published in The Lancet and hailed as a watershed moment for women's health. The change is not semantic window dressing. It reflects what researchers have understood for years: the condition involves hormonal and metabolic dysfunction that extends far beyond the ovaries. It involves insulin resistance, inflammation, and endocrine imbalance. The old name had obscured this reality, leading to decades of delayed diagnoses, fragmented care, and women whose symptoms were overlooked or dismissed.
Martin, now 34 and British-Singaporean, born in Hong Kong, eventually moved beyond the terror of that diagnosis. She became a personal trainer. She rebuilt her relationship with her body not through pharmaceutical intervention—specifically, not through the GLP-1 receptor agonists that have become fashionable for weight management—but through deliberate lifestyle change. Her story, told now as the medical world recalibrates its understanding of her condition, illustrates something the rebranding was designed to address: that comprehensive care, accurate naming, and a full picture of what the body is actually experiencing can make the difference between a woman feeling broken and a woman feeling capable of healing.
The stigma attached to the old name ran deep. PCOS sounded like a reproductive problem, a fertility issue, something that belonged in whispered conversations with an obstetrician. It sounded like the ovaries had failed. Women reported feeling shame, feeling defective. Doctors, working from incomplete frameworks, often treated only the most visible symptom—irregular periods or infertility—rather than addressing the metabolic dysfunction underneath. Some women waited years for diagnosis. Others received it and then received little guidance on what to do with it.
The rebranding aims to shatter that fragmentation. PMOS acknowledges that this is a systemic condition affecting multiple endocrine and metabolic pathways. It opens the door to more comprehensive screening, to doctors asking the right questions about insulin sensitivity and inflammation, to women understanding that their fatigue or their difficulty losing weight or their mood changes are not character flaws but symptoms of a treatable metabolic disorder. It signals, finally, that this is not a niche women's issue but a significant public health challenge affecting tens of millions of people worldwide.
Martin's journey—from the shock of diagnosis to reclaiming her health through sustained lifestyle intervention—now unfolds against this backdrop of medical reckoning. Her story is one of many that the new terminology may help illuminate more clearly, and more quickly, for the next generation of women whose bodies begin to rebel at 22, or 25, or 32, and who deserve to understand why.
Notable Quotes
I remember being told that I might not be able to have kids and that the cysts might be cancerous. I was terrified.— Ashleigh Martin, on her initial diagnosis
The Hearth Conversation Another angle on the story
When you first heard PCOS, what did that word make you think was wrong with you?
I thought my ovaries had failed me. That's what the name suggested—that the problem was the cysts, that my reproductive system was broken. Nobody explained that my body was struggling with insulin, with inflammation, with how it processed energy.
And when you started training as a personal trainer, did that understanding shift?
Completely. I realized the weight gain, the irregular periods, the fatigue—they were all connected to how my body was metabolizing food, managing hormones. It wasn't about willpower or discipline. It was about working with my actual physiology, not against it.
Why did you choose not to use GLP-1s, given how much easier that path seemed?
Because I wanted to understand my body, not just suppress my appetite. The drugs work for some people, but they didn't address what was actually happening inside me. I needed to fix the metabolic dysfunction, not mask it.
Do you think the name change to PMOS would have helped you at 22?
Absolutely. If a doctor had said, "This is a metabolic and hormonal disorder affecting multiple systems," I would have understood that I needed to look at sleep, stress, insulin resistance, inflammation—not just accept that my ovaries were broken. The name matters because it changes what doctors look for and what women expect from treatment.
What do you want women newly diagnosed to know?
That you're not broken. Your body is trying to tell you something. Listen to it. Work with someone who understands the whole picture, not just one symptom.